{
    "eu_pnumber": "EU/1/21/1541",
    "eu_prime_initial": {
        "value": "False",
        "date": "2023-01-07"
    },
    "odwar_url": "404_url_not_found",
    "ema_od_number": "__SCRAPER_NOT_FOUND__",
    "eu_aut_status": [
        {
            "value": "ACTIVE",
            "date": "2023-01-07"
        }
    ],
    "ema_rapp": "john joseph borg",
    "eu_od_con": "__SCRAPER_NOT_FOUND__",
    "eu_od_date": "__SCRAPER_NOT_FOUND__",
    "ema_corapp": "__SCRAPER_NOT_FOUND__",
    "eu_mah_initial": {
        "value": "Accord Healthcare S.L.U.",
        "date": "2023-01-07"
    },
    "atc_code": "L01EA02",
    "eu_od_initial": {
        "value": "__SCRAPER_NOT_FOUND__",
        "date": "2023-01-07"
    },
    "eu_accel_assess_g": "False",
    "ema_procedure_start_initial": "2019-06-03",
    "eu_od_pnumber": "__SCRAPER_NOT_FOUND__",
    "assess_time_days_total": 969,
    "chmp_opinion_date": "2022-01-27",
    "eu_od_sponsor": [
        {
            "value": "__SCRAPER_NOT_FOUND__",
            "date": "2023-01-07"
        }
    ],
    "assess_time_days_active": "Not found",
    "eu_referral": "False",
    "eu_od_comp_date": "__SCRAPER_NOT_FOUND__",
    "eu_aut_date": "2022-03-24",
    "assess_time_days_cstop": "Not found",
    "eu_od_number": "__SCRAPER_NOT_FOUND__",
    "eu_indication_initial": {
        "value": "dasatinib accordpharma is indicated for the treatment of adult patients with: \uf0a7 newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. \n \uf0a7 chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. \n \uf0a7 ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.\n\n dasatinib accordpharma is indicated for the treatment of paediatric patients with: \n \uf0a7 newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. \n \uf0a7 newly diagnosed ph+ all in combination with chemotherapy.\n",
        "date": "2023-01-07"
    },
    "eu_aut_type_initial": {
        "value": "__SCRAPER_NOT_FOUND__",
        "date": "2023-01-07"
    },
    "eu_nas": false,
    "eu_aut_type_current": [
        {
            "value": "standard",
            "date": "2023-01-07"
        }
    ],
    "ema_omar_condition": "__SCRAPER_NOT_FOUND__",
    "eu_legal_basis": [
        "article 10.1"
    ],
    "ec_decision_time_days": 345,
    "aut_url": "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/dec_154987_en.pdf",
    "ema_reexamination": "False",
    "smpc_url": "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/anx_154987_en.pdf",
    "eu_procedures_todo": [
        {
            "eu_referral": false,
            "eu_suspension": false
        }
    ],
    "epar_url": "https://www.ema.europa.eu/documents/assessment-report/dasatinib-accordpharma-epar-public-assessment-report_en.pdf",
    "eu_atmp": false,
    "eu_med_type": "small molecule",
    "orphan_status": "h",
    "eu_brand_name_current": [
        {
            "value": "Dasatinib Accordpharma",
            "date": "2023-01-07"
        }
    ],
    "eu_orphan_con_current": [
        {
            "value": "__SCRAPER_NOT_FOUND__",
            "date": "2023-01-07"
        }
    ],
    "eu_brand_name_initial": {
        "value": "Dasatinib Accordpharma",
        "date": "2023-01-07"
    },
    "ema_number": "EMEA/H/C/005317",
    "ema_number_check": false,
    "eu_suspension": "False",
    "ema_number_id": "5317",
    "ema_number_certainty": "1.0",
    "omar_url": "404_url_not_found",
    "active_substance": "dasatinib",
    "eu_mah_current": [
        {
            "value": "Accord Healthcare S.L.U.",
            "date": "2023-01-07"
        }
    ]
}